Several recent studies have reported that I-FABP, which reflects mucosal compromise, can be used as a promising biomarker of acute intestinal mucosa damage, including necrotizing enterocolitis (NEC) in preterm infants, and assesses the extent and severity of intestinal involvement even before the development of disease [2,3,4,5,6]. The gene discussed is FABP2; the disease is necrotizing enterocolitis.